Pre- treatment protein landscape in HER2-negative breast cancer treated with carboplatin in a neoadjuvant chemotherapy setting

被引：0
|
作者：
Dahle, Maria Aanesland
Egeland, Eivind Valen
Prasmickaite, Lina
Lingjaerde, Ole Christian
Russnes, Hege
Garred, Oystein
Smebye, Marianne L.
Skjerven, Helle
Schlichting, Ellen
Naume, Bjorn
Maelandsmo, Gunhild
Engebraaten, Olav
Haugen, Mads H.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2170
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2170
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Human clinical trial using diagnostic ultrasound and microbubbles to enhance neoadjuvant chemotherapy in HER2-negative breast cancer
    Zhou, Biqiang
    Lian, Qingshu
    Jin, Chunchun
    Lu, Jianghao
    Xu, Lifeng
    Gong, Xuehao
    Zhou, Peng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
    Ho Hyun Ryu
    Sei Hyun Ahn
    Seon Ok Kim
    Jeong Eun Kim
    Ji sun Kim
    Jin-Hee Ahn
    Kyung Hae Jung
    Sung-Bae Kim
    Beom Seok Ko
    Jong Won Lee
    Byung Ho Son
    Hee Jung Shin
    Hak Hee Kim
    Gyung yub Gong
    Hee Jeong Kim
    Scientific Reports, 11
  • [43] The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer.
    Brase, J. C.
    Gehrmann, M. C.
    Petry, C.
    Weber, K. E.
    Schmidt, M.
    Koelbl, H.
    Brauch, H.
    Schwab, M.
    Mueller, V.
    Jaenicke, F.
    Rody, A.
    Kaufmann, M.
    Filipits, M.
    Gnant, M.
    Denkert, C.
    Loibl, S.
    von Minckwitz, G.
    Kronenwett, R.
    CANCER RESEARCH, 2011, 71
  • [44] Sequence of anthracyclines and taxanes in the neoadjuvant chemotherapy of HER2-negative breast cancer: Experience of a Brazilian oncological center.
    Preto, Daniel D'Almeida
    Nicolau Sanches, Andre Octavio
    Azevedo Barroso, Alison Wagner
    Moretto Carbinatto, Alessandra Caroline
    Veneziani, Ana Lima
    Kons, Georgia
    Budib, Maria
    Zaffari Safro, Maria Augusta
    Faria Pinto, Gustavo Sanches
    Bello Secco, Alan Felipe
    Costa Zorzetto, Marina Moreira
    Lacerda, Domicio
    Paiva, Carlos Eduardo
    Souza, Cristiano de Padua
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer
    Lv, Zhi-Dong
    Song, Hong-Ming
    Niu, Zhao-He
    Nie, Gang
    Zheng, Shuai
    Xu, Ying-Ying
    Gong, Wei
    Wang, Hai-Bo
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [46] Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
    Ryu, Ho Hyun
    Ahn, Sei Hyun
    Kim, Seon Ok
    Kim, Jeong Eun
    Kim, Ji Sun
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Kim, Sung-Bae
    Ko, Beom Seok
    Lee, Jong Won
    Son, Byung Ho
    Shin, Hee Jung
    Kim, Hak Hee
    Gong, Gyung Yub
    Kim, Hee Jeong
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [47] Comparative Toxicities of Neoadjuvant Chemotherapy With or Without Bevacizumab in HER2-Negative Breast Cancer Patients: A Meta-analysis
    Wang, Bi-Cheng
    Fu, Chen
    Xie, Lin-Ka
    Kuang, Bo-Hua
    Zhao, Yan-Xia
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (06) : 517 - 525
  • [48] A predictor model for pathological CR after neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer
    Fujiki, Yoshitaka
    Yamamoto, Yutaka
    Tomiguchi, Mai
    Sueta, Aiko
    Takeshita, Takashi
    Ibusuki, Mutsuko
    Iwase, Hirotaka
    CANCER SCIENCE, 2018, 109 : 654 - 654
  • [49] Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
    Rigter, L. S.
    Loo, C. E.
    Linn, S. C.
    Sonke, G. S.
    van Werkhoven, E.
    Lips, E. H.
    Warnars, H. A.
    Doll, P. K.
    Bruining, A.
    Mandjes, I. A.
    Peeters, M. J. Vrancken
    Wesseling, J.
    Gilhuijs, K. G.
    Rodenhuis, S.
    BRITISH JOURNAL OF CANCER, 2013, 109 (12) : 2965 - 2972
  • [50] Neoadjuvant Therapy for weak receptor-positive/HER2-negative Breast Cancer
    Judith Lorenz, Kuenzell
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (11) : 1124 - 1124
12345